PRECIRIX’ platform allows the design and development of novel
radiopharmaceuticals or targeted radioligand therapies, a
technology in which radionuclides are attached to ligands that
direct them to their specific target on the cancer cell. The
radioactive payload is delivered in a highly selective manner to the
tumor, limiting radiation to the rest of the body.
Our technology platform facilitates development of sdAbs for multiple targets, in combination with different isotopes and applicability in various settings.
On target in minutes after IV infusion anywhere in the body. Deep tumor penetration and prolonged tumor retention. Rapid renal clearance of unbound product.
Direct cell killing and bystander effects.
Cancer cells
Specific epitopes
Tumor microenvironment
Alpha emitters
Beta emitters
Therapeutic
Patient selection
Combination therapy
CAM-H2, consists of an HER2-targeting single-domain antibody linked to iodine-131. This targeted radioligand therapy is being developed for the treatment of patients with metastatic HER2-positive cancer indications, such as breast and gastric adenocarcinoma.
CAM-FAP, a single-domain antibody construct targeting fibroblast activation protein alpha is nearing IND readiness.
In addition to the lead program, the company has two compounds in advanced preclinical stage, targeting fibroblast activation protein and folate receptor alpha.
PRECIRIX’ research program further focuses on the evaluation of different linkers, isotopes and new sdAbs.
| Lead generation |
Lead optimization |
Pre-clinical | Phase Ⅰ | Phase Ⅰ/Ⅱ | Phase Ⅲ | Market | |
|---|---|---|---|---|---|---|---|
| CAM-H2 HER2+ Metastatic Cancer | |||||||
| CAM-FAP FAP+ cancer | |||||||
| Early programs Platform | |||||||
|
|||||||
The company is conducting a Phase I/II study to evaluate CAM-H2 treatment in patients with advanced / metastatic HER2-positive breast and gastroesophageal cancer.
Research demonstrated the specific uptake of CAM-H2 in brain lesions of patients with brain metastases from HER2-positive breast carcinoma. Therefore, the phase I/II trail will evaluate the impact of CAM-H2 on brain metastases, which are frequently observed in metastatic breast cancer.
The dose-escalation phase of the trial has been finalized, demonstrating safety and specific targeting of cancer cells.
Relevant literature
Presentations
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.